Tocilizumab for chronic active antibody-mediated rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney function (eGFR) must be above 25 mL/min.
- A kidney biopsy must show certain changes (chronicity score less than 8 and IFTA less than 40%).
- You must have had the Epstein-Barr virus (EBV) in the past (test positive for antibodies).
- You cannot have an active infection or a recent cancer (unless in remission for over 2 years).
- Your platelet count and liver function tests must be normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This is a study of people who have a specific type of early rejection after a kidney transplant (“acute antibody-mediated rejection”). The study aims to understand what treatments work and why, to improve future care.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.